Stock ATORX ALLIGATOR BIOSCIENCE AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Alligator Bioscience AB

Equities

ATORX

SE0000767188

Delayed Nasdaq Stockholm
Other stock markets
 04:03:49 2024-06-10 am EDT 		5-day change 1st Jan Change
1.14 SEK -1.38% Intraday chart for Alligator Bioscience AB +0.71% +65.46%
May. 23 Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting CI
May. 21 US FDA Grants Investigational New Drug Clearance for Alligator Bioscience's Late-stage Gastric Cancer Treatment Trial MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting
US FDA Grants Investigational New Drug Clearance for Alligator Bioscience's Late-stage Gastric Cancer Treatment Trial
Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer
Alligator Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024
Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement
Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board
Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
Correction: Alligator Bioscience Seeks SEK151 Million Capital Raising, Enters SEK59 Million Bridge Loan
Alligator Bioscience Seeks SEK151 Capital Raising, Enters SEK59 Million Bridge Loan
Alligator Bioscience to Trim Workforce Amid Restructuring Program
Alligator Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Alligator Bioscience Plans to Adjust Size of Organization with Reduction of Approximately 20% to 25% of Current Workforce
Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer
Alligator Bioscience Secures US Patent for Cancer Treatment Antibody
Alligator Bioscience AB Appoints Bertil Brinck as Chairman of the Nomination Committee
Alligator Bioscience AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab
Alligator Bioscience Chief Operating Officer to Resign
Alligator Bioscience AB Announces Resignation of Malin Carlsson as Chief Operating Officer At the End of October
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATORX Stock
  4. News Alligator Bioscience AB
  5. Other languages